FogPharma Stock
HealthTechLooking to sell FogPharma stock or options?
FogPharma specializes in creating cell-penetrating mini proteins (CPMPs) aimed at targeting and neutralizing cancer-causing proteins within cancer cells. These CPMPs represent a groundbreaking class of medicines capable of reaching drug targets that conventional therapies cannot address, allowing physicians to effectively treat diseases related to cancer.
Alex Gorsky, Marshall Wace, Deerfield Management, Cormorant Asset Management, Horizons Ventures, WuXi AppTec, SymBiosis Capital Management, T. Rowe Price Group, HBM Healthcare Investments, RA Capital Management, The Invus Group, GV, Blue Pool Capital, Foresite Capital, Samsara BioCapital, General Catalyst, PagsGroup, Pivotal Life Sciences, Casdin Capital, Leerink Partners, Fidelity Management & Research, HBM Partners, Rock Springs Capital, venBio, 6 Dimensions Capital.
Our available services for this company
Management Team
Board Members
FogPharma’s stock FAQs
FogPharma is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize FogPharma stock. Depending on FogPharma’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange FogPharma stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of FogPharma stock in two ways. First, FogPharma employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your FogPharma stock. Note that all transactions in FogPharma shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
FogPharma stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for FogPharma stock. Typically, shares of private companies like FogPharma are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Mar 2024, FogPharma is reported to have closed an equity financing in which the investors valued the company at $492M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of FogPharma shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because FogPharma is not currently publicly traded, it does not have a ticker symbol.
FogPharma has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though FogPharma is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on FogPharma shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
